TY - JOUR
T1 - Consumer willingness to pay for a hypothetical Zika vaccine in Brazil and the implications
AU - Muniz Júnior, Roberto Lúcio
AU - Godói, Isabella Piassi
AU - Reis, Edna Afonso
AU - Garcia, Marina Morgado
AU - Guerra-Júnior, Augusto Afonso
AU - Godman, Brian
AU - Ruas, Cristina Mariano
N1 - Funding Information:
I Piassi Godói received financial support from CAPES (Coordenação de Aperfeiçoamento de Pessoal de Nível Superior). The project was also in part supported by a Newton Advanced Fellowship by the Academy of Medical Sciences to AA Gerrra Júnior through the UK Government’s Newton Fund programme. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.
Funding Information:
IPG received financial support from CAPES (Coordenação de Aperfeiçoamento de Pessoal de Nível Superior). The project was also in part supported by a Newton Advanced Fellowship by the Academy of Medical Sciences to Augusto Afonso Guerra Júnior through the UK Government’s Newton Fund programme.
Publisher Copyright:
© 2018, © 2018 Informa UK Limited, trading as Taylor & Francis Group.
PY - 2019/7/4
Y1 - 2019/7/4
N2 - ABSTRACT : Background: Zika virus is a newly emerging infection, associated with increasingly large outbreaks especially in tropical countries such as Brazil. A future Zika vaccine can contribute to decreasing the number of cases and associated complications. Information about consumers’ willingness to pay (WTP) for a hypothetical Zika vaccine can help price setting discussions in the future in Brazil, starting with the private market. Methods: A cross-sectional study conducted among residents of Minas Gerais, Brazil, regarding their WTP for a hypothetical Zika Vaccine. The mean effective protection was 80%, with the possibility of some local and systemic side- effects. Results: 517 people were interviewed. However, 28 would not be vaccinated even if the vaccine was free. Most of the resultant interviewees (489) were female (58.2%), had completed high school (49.7%), were employed (71.2%), had private health insurance (52.7%), and did not have Zika (96.9%). The median individual maximum WTP for this hypothetical Zika vaccine (one dose) was US$31.34 (BRL100.00). Conclusion: Such discussions regarding WTP can contribute to decision-making about prices once a Zika vaccine becomes available in Brazil alongside other ongoing programs to control the virus.
AB - ABSTRACT : Background: Zika virus is a newly emerging infection, associated with increasingly large outbreaks especially in tropical countries such as Brazil. A future Zika vaccine can contribute to decreasing the number of cases and associated complications. Information about consumers’ willingness to pay (WTP) for a hypothetical Zika vaccine can help price setting discussions in the future in Brazil, starting with the private market. Methods: A cross-sectional study conducted among residents of Minas Gerais, Brazil, regarding their WTP for a hypothetical Zika Vaccine. The mean effective protection was 80%, with the possibility of some local and systemic side- effects. Results: 517 people were interviewed. However, 28 would not be vaccinated even if the vaccine was free. Most of the resultant interviewees (489) were female (58.2%), had completed high school (49.7%), were employed (71.2%), had private health insurance (52.7%), and did not have Zika (96.9%). The median individual maximum WTP for this hypothetical Zika vaccine (one dose) was US$31.34 (BRL100.00). Conclusion: Such discussions regarding WTP can contribute to decision-making about prices once a Zika vaccine becomes available in Brazil alongside other ongoing programs to control the virus.
KW - Arbovirosis
KW - Brazil
KW - Zika
KW - contingent valuation
KW - reimbursement
KW - vaccine
KW - willingness to pay
UR - http://www.scopus.com/inward/record.url?scp=85058090187&partnerID=8YFLogxK
U2 - 10.1080/14737167.2019.1552136
DO - 10.1080/14737167.2019.1552136
M3 - Article
C2 - 30468095
AN - SCOPUS:85058090187
SN - 1473-7167
VL - 19
SP - 473
EP - 482
JO - Expert Review of Pharmacoeconomics and Outcomes Research
JF - Expert Review of Pharmacoeconomics and Outcomes Research
IS - 4
ER -